First Quarter 2018 Investor Presentation

Investor Presentation First three months of 2018 Slide 68 The GLP-1 segment accounts for around 11% of total diabetes care market value in Europe GLP-1 value in bDKK European GLP-1 market VictozaⓇ exenatide VictozaⓇ value market share in Europe VictozaⓇ exenatide - dulaglutide other 87654321 0 Feb 2013 ▪dulaglutide Share of total other GLP-1 value diabetes care market share market 10% 100% CAGR value¹: 21.2% 8% 80% +6% 60% + 4% 40% - 2% 20% 0% 0% Feb 2018 Feb 2013 1 CAGR for 5-year period. Source: IQVIA monthly MAT Feb, 2018 value figures (DKK) changing diabetes® 57% 28% 12% 2% Feb 2018 Source: IQVIA monthly MAT Feb, 2018 value figures (DKK), market share does not add up to 100% due to rounding novo nordisk

View entire presentation